This application's broad, long-term objective is to improve the health of millions of Americans with or at risk for obesity- associated non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease in the United States. After successfully validating MR imaging biomarkers for hepatic steatosis, the earliest histologic feature of NAFLD, in the first cycle of this grant, this competitive renewal focuses on hepatic fibrosis and inflammation, features of non-alcoholic steatohepatitis (NASH), the aggressive subtype of NAFLD that can progress to cirrhosis, liver cancer, and liver-related death. MR elastography (MRE), a noninvasive method to quantify tissue stiffness, is the leading imaging-based technique for assessing liver fibrosis in NAFLD, but the true diagnostic performance of MRE for detecting fibrosis and NASH cross-sectionally, and for monitoring their change longitudinally, is incompletely understood. By optimizing and rigorously evaluating MRE for these purposes, we will address major knowledge and technical gaps that have obscured the appropriate utilization of this technology in clinical care and research.
Aim 1 : Optimize MRE wavefield generation in severe obesity, applicable to both conventional 2D- and advanced 3D-MRE.
Aim 2 : Characterize the precision profile of conventional 2D- and advanced 3D-MRE in severe obesity (same-day repeatability, field-strength reproducibility, reader reproducibility, between-day reproducibility).
Aim 3 : Determine the accuracy of conventional 2D- and advanced 3D-MRE in severe obesity to a) diagnose fibrosis and NASH cross-sectionally and b) monitor change in fibrosis and resolution of NASH longitudinally. Significance: By determining the true diagnostic performance of conventional 2D- and advanced 3D-MRE for detecting and monitoring fibrosis and NASH in bariatric patients, the proposed research will inform the appropriate utilization of MRE for clinical care, clinical trials, and other research in obesity-associated NAFLD. Additionally, if the research confirms the promise of advanced 3D-MRE to detect early-stage NASH, this will represent a game-changing new technical capability. Innovation: This application brings innovation in three thematic areas: (1) Study design: prospective cross-sectional and longitudinal study in bariatric patients, a technically challenging population with balanced disease severity distribution ideal for addressing the scientific aims. (2) Wavefield generation: testing of new flexible drivers designed to generate high-quality wavefields. (3) MRE analysis: rigorous testing of advanced 3D-MRE reconstruction and analysis methods that in preliminary animal and human studies show promise for diagnosing early-stage NASH. Research design & methods: Phase 1 of this 2-site study will optimize MRE wavefield generation in severe obesity by identifying the driver type and position that maximize MRE precision. Using that optimal driver type/position, Phase 2 will enroll 100 severely obese adults (50/site) undergoing weight-loss surgery in a prospective longitudinal study with 2D- and 3D-MRE at multiple time points. Reference standards for the presence of fibrosis and NASH, and their change, will include expert consensus scoring and quantitative image analysis of paired contemporaneous biopsies obtained at surgery and at 6 months. Complementary anthropometric, laboratory, and MRI measures will be acquired to identify factors that affect MRE performance and develop hypotheses for future studies. !

Public Health Relevance

The broad, long-term objective of our research is to improve the health of the nearly 100 million Americans with or at risk for non-alcoholic fatty liver disease. This disease can progress to liver failure, liver cancer, and liver-related death. We seek to develop and validate imaging methods that can diagnose this disease and determine its severity without a biopsy. Such methods will reduce the need for biopsy, permit earlier diagnosis, and facilitate more effective treatment, thereby preventing its long-term complications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK088925-08
Application #
9771455
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Doo, Edward
Project Start
2010-09-15
Project End
2022-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
8
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Kennedy, Paul; Wagner, Mathilde; Castéra, Laurent et al. (2018) Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 286:738-763
Bydder, Mark; Hamilton, Gavin; de Rochefort, Ludovic et al. (2018) Sources of systematic error in proton density fat fraction (PDFF) quantification in the liver evaluated from magnitude images with different numbers of echoes. NMR Biomed 31:
Hong, Cheng William; Wolfson, Tanya; Sy, Ethan Z et al. (2018) Optimization of region-of-interest sampling strategies for hepatic MRI proton density fat fraction quantification. J Magn Reson Imaging 47:988-994
Hong, Cheng William; Mamidipalli, Adrija; Hooker, Jonathan C et al. (2018) MRI proton density fat fraction is robust across the biologically plausible range of triglyceride spectra in adults with nonalcoholic steatohepatitis. J Magn Reson Imaging 47:995-1002
Yokoo, Takeshi; Serai, Suraj D; Pirasteh, Ali et al. (2018) Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis. Radiology 286:486-498
Roberts, Nathan T; Hernando, Diego; Holmes, James H et al. (2018) Noise properties of proton density fat fraction estimated using chemical shift-encoded MRI. Magn Reson Med 80:685-695
Fazeli Dehkordy, Soudabeh; Fowler, Kathryn J; Wolfson, Tanya et al. (2018) Technical report: gadoxetate-disodium-enhanced 2D R2* mapping: a novel approach for assessing bile ducts in living donors. Abdom Radiol (NY) 43:1656-1660
Mamidipalli, Adrija; Hamilton, Gavin; Manning, Paul et al. (2018) Cross-sectional correlation between hepatic R2* and proton density fat fraction (PDFF) in children with hepatic steatosis. J Magn Reson Imaging 47:418-424
Caussy, Cyrielle; Reeder, Scott B; Sirlin, Claude B et al. (2018) Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials. Hepatology 68:763-772
Campo, Camilo A; Hernando, Diego; Schubert, Tilman et al. (2017) Standardized Approach for ROI-Based Measurements of Proton Density Fat Fraction and R2* in the Liver. AJR Am J Roentgenol 209:592-603

Showing the most recent 10 out of 125 publications